BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 30954369)

  • 1. A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I.
    Balestra D; Scalet D; Ferrarese M; Lombardi S; Ziliotto N; C Croes C; Petersen N; Bosma P; Riccardi F; Pagani F; Pinotti M; van de Graaf SFJ
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
    Mohamed S; Kambal MA; Al Jurayyan NA; Al-Nemri A; Babiker A; Hasanato R; Al-Jarallah AS
    BMC Res Notes; 2013 Sep; 6():362. PubMed ID: 24016420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Caenorhabditis elegans K10C2.4 gene encodes a member of the fumarylacetoacetate hydrolase family: a Caenorhabditis elegans model of type I tyrosinemia.
    Fisher AL; Page KE; Lithgow GJ; Nash L
    J Biol Chem; 2008 Apr; 283(14):9127-35. PubMed ID: 18227072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of human fumarylacetoacetate hydrolase domain-containing protein 1 (FAHD1) as a novel mitochondrial acylpyruvase.
    Pircher H; Straganz GD; Ehehalt D; Morrow G; Tanguay RM; Jansen-Dürr P
    J Biol Chem; 2011 Oct; 286(42):36500-8. PubMed ID: 21878618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).
    Chi H; Gan C; Jiang Y; Chen D; Qiu J; Yang Q; Chen Y; Wang M; Yang H; Jiang W; Li Q
    Mol Genet Genomic Med; 2023 Jan; 11(1):e2090. PubMed ID: 36369907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G; Tanguay RM
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
    Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
    BMC Genet; 2001; 2():9. PubMed ID: 11476670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
    Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.
    Ibarra-González I; Fernández-Lainez C; Alcántara-Ortigoza MA; González-Del Angel A; Fernández-Henández L; Guillén-López S; Belmont-Martínez L; López-Mejía L; Varela-Fascinetto G; Vela-Amieva M
    Mol Genet Genomic Med; 2019 Dec; 7(12):e937. PubMed ID: 31568711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
    Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
    Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
    Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.